Trial Profile
The effects of a humanized anti-IL-5 [interleukin 5] monoclonal antibody (SB-240563 [mepolizumab]) on asthma control, airway eosinophilia and the degree to which corticosteroid treatment can be reduced to maintain control.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma; Bronchitis
- Focus Therapeutic Use
- 05 Mar 2009 Results reported in New England Journal of Medicine.
- 05 Mar 2009 Status changed from active, no longer recruiting to completed.
- 30 Sep 2006 New trial record.